Human Embryonic Stem Cells (hESC) Market Report

Human Embryonic Stem Cells (hESC) Market Analysis By Application (Regenerative Medicines, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), By Country (U.S., UK, Germany, Japan, China), And Segment Forecasts, 2014 - 2025

Published: February 2017  |  100 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-394-2

Industry Insights

The global Human Embryonic Stem Cells (hESCs) market size was valued at USD 494.7 million in 2015. These are the pluripotent cells that possess the ability to get differentiated into all germ layers. Rising demand owing to the increasing incidence of genetic disorders is anticipated to boost growth.

Research carried out in order to utilize them for disease eradication is expected to support in projected growth. Controlled differentiation that can be achieved in tissue committed cells through the co-culturing with basic fibroblast growth factor is expected to induce growth.

UK human embryonic stem cells market, by application, 2014-2025 (USD Million)

UK human embryonic stem cells market

Active involvement of the organizations for developing alternative ways of production of hESCs is anticipated to drive progress. For instance, Science University and Oregon Health is engaged in developing blastocyst staged embryo of around 150 cells in order to provide hESC source.

Stem cells derived through such techniques can be converted into liver, nerve, and heart tissues. Although this requires significant R&D for implementation as safe and effective treatment options, but these can be applied in developing biologics for regenerative medicine.

Moreover, implementation of ESC based animal models in the academic institutes serves a considerably important role for projected growth. In 2014, 70% of trials were sponsored by academic institutions and 30% by the private sector.

Rapid advancements in this vertical include protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of various disease models, and evaluation of therapeutic potential in treating incurable diseases.

Advantages associated with their use is projected to boost the demand in the research community. These advantages include presence of pluripotent markers, production of high levels of telomerase, and ability of being coaxed into a whole battery of tissue types.

Accelerated uptake of ESC based cell therapy on in vivo and in vitro principle is expected to fuel growth through to 2024. Research carried out to reduce the problems of immunogenicity and teratoma induction is expected to drive R&D in industry.

However, implementation remains a controversial topic due to diverse views in context to moral and legal status of early embryo cell lines. This has led to conflicting and provocative claims inside and outside scientific community pertaining to their biomedical potential.

Human embryonic stem cells market, by region, 2015 (USD Million)

Human embryonic stem cells market

Application Insights

Applicability for inducing differentiation into wide range of tissues is attributive for the largest share of regenerative medicine. The differentiated cells are further used for therapeutic applications in regenerative medicine.

hESC research is anticipated to have considerable potential in treatment of disorders wherein cellular loss is known to occur. These disorders include Parkinson's disease, post-myocardial infarction, lung disorders, and Type 1 diabetes mellitus.

Furthermore, unique properties of hESC based models enables them to revolutionize the earliest steps of drug discovery. Particularly, pathological and toxicology modelling can be performed by provision of physiological models for different human cell types.

Regional Insights

Variation in the policies across the globe is expected to impact the global market of embryonic stem cell development. North America dominated the market with respect to revenue generation as a result of presence of several prominent entities incorporated in the U.S.

As hESC research is permitted in Belgium, Finland, UK, Denmark, Sweden, and Netherlands, Europe is estimated to follow North America in revenue generation. Moreover, the government of Asian countries are supportive for hESC research thus boosting growth in this region.

Significant involvement of Japanese government in development of cell line based therapies is a significant factor and is expected to provide lucrative growth avenues. Presence of government-backed efforts to create a bank of iPSC lines is attributive to drive progress.

Competitive Insights

Some of the prominent players operating in this vertical include Thermo Fisher Scientific, Inc.;

CellGenix GmbH, ESI BIO, PromoCell GmbH, Lonza, Kite Pharma, LifeCell, and International Stem Cell Corporation.

Most of these companies are engaged in strategic endeavors in order to maintain the market share. For instance, Astella Therapeutics acquired Ocata Therapeutics which is anticipated to enhance its presence with respect to cell therapy.

The players are also in involved in portfolio expansion by introduction of culture media that is designed to optimize the expansion rate of hESC. Presence of products in clinical trials attributive to influence progress.

Report Scope

Attribute

Details

Base year for estimation

2015

Actual estimates/Historical data

2014 & 2015

Forecast period

2016 - 2025

Market representation

Revenue in USD Million and CAGR from 2016 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, UK, Germany, Japan, China, Brazil, South Africa.

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at regional & country level and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this report, Grand View Research has segmented the human embryonic stem cells market on the basis of application and regions:

  • Application Outlook (Revenue, USD Million; 2014 - 2025)

    • Regenerative medicine

    • Stem cell biology research

    • Tissue engineering

    • Toxicology testing

  • Regional Outlook (Revenue, USD Million; 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

    • Middle East and Africa (MEA)

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $3,450
Multi User - $6,450
Enterprise User - $8,450

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA